Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Still Holds Technician, Official Of Shanghai Pharma Branch

This article was originally published in PharmAsia News

Executive Summary

A technician and a company official of Shanghai Pharmaceutical Group in China have been detained by Chinese police for possible involvement in last year's tainted-drug scandal, according to a sales official. The head of cancer drug sales for the company's Shanghai Hualian Pharmaceutical subsidiary said a technician at the branch mistakenly added a vincristine sulfate compound to an anti-cancer methotrexate drug, causing further injury to a leukemia patient and reports of other problems with the drug, all in China. The incident sparked a government investigation that led the State FDA to accuse the company of "systematically covering up irregularities in manufacturing." The Hualian sales official said the branch had been recycling leftover materials from methotrexate's production process as part of a cost-cutting effort. (Click here for more - subscription may be required

You may also be interested in...



Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis

In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel